ACT-1 Multicenter investigator-initiated registration-directed Phase 2 study of E7090 in subjects with advanced or recurrent solid tumors with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial

Background: Genetic alterations of FGFRs are known to play an important role in the proliferation, survival, and migration of cancer cells as well as tumor angiogenesis and drug resistance. E7090 is an orally available selective tyrosine kinase inhibitor for FGFR1-3. A global Phase 2 study of E7090...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Masamichi, Chiba, Yohei, Sudo, Kazuki, Kojima, Yuki, Okuma, Hitomi, Kohsaka, Shinji, Ichimura, Masahiko, Okita, Natsuko, Nakamura, Kenichi, Machida, Ryunosuke, Kinoshita, Ichiro, Takahashi, Masanobu, Matsubara, Junichi, Kusaba, Hitoshi, Yonemori, Kan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664618/
http://dx.doi.org/10.1093/noajnl/vdab159.033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664618/
http://dx.doi.org/10.1093/noajnl/vdab159.033

Ejemplares similares